Imugene Ltd Azer-cel Trial Update Transcript
Thank you for standing by, and welcome to the Imugene investor webinar, following the announcement earlier this week of new data from the company's Phase 1b trial of its Azer-cel technology. Joining us for Imugene today, we have the CEO and Managing Director, Leslie Chong; joined by Chief Medical Officer. Dr. Paul Woodard. (Event Instructions) To kick off I'll hand it over to Lesley.
Thank you so much, Matt. Good morning, good evening wherever you're calling in from. Great to have you. We are excited to talk about Azer-cell this morning. So Imugene is listed on the ASX as IMU as a ticker. We are leaders in innovations and cancer treatments and I can share with you why. So we have at clinical stage cancer products in CAR-T cell therapy as well as oncolytic viruses.
And we were currently at market cap around AUD500 million with a cash position of AUD93.1 million, this is currently with without our R&D rebate. So that's assumed to be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
